Intevac Announces Third Quarter 2019 Financial Results
Mon, October 28 2019
“In the third quarter, we continued to gain momentum as we drove our strategies for revenue growth and profitability,” commented
($ Millions, except per share amounts) |
Q3 2019 |
Q3 2018 |
||||||||||
GAAP Results |
Non-GAAP Results |
GAAP Results |
Non-GAAP Results |
|||||||||
Net Revenues |
$ |
26.3 |
$ |
26.3 |
$ |
19.5 |
$ |
19.5 |
||||
Operating Loss |
$ |
(0.4) |
$ |
(0.4) |
$ |
(1.1) |
$ |
(1.1) |
||||
Net Loss |
$ |
(0.5) |
$ |
(0.5) |
$ |
(1.1) |
$ |
(1.1) |
||||
Net Loss per Share |
$ |
(0.02) |
$ |
(0.02) |
$ |
(0.05) |
$ |
(0.05) |
||||
|
Nine Months Ended |
Nine Months Ended |
||||||||||
|
|
|||||||||||
GAAP Results |
Non-GAAP Results |
GAAP Results |
Non-GAAP Results |
|||||||||
Net Revenues |
$ |
73.4 |
$ |
73.4 |
$ |
63.5 |
$ |
63.5 |
||||
Operating Loss |
$ |
(3.4) |
$ |
(3.4) |
$ |
(6.1) |
$ |
(6.0) |
||||
Net Loss |
$ |
(4.1) |
$ |
(4.0) |
$ |
(6.4) |
$ |
(6.3) |
||||
Net Loss per Share |
$ |
(0.18) |
$ |
(0.18) |
$ |
(0.29) |
$ |
(0.28) |
Intevac’s non-GAAP adjusted results exclude the impact of the following, where applicable: (1) changes in fair value of contingent consideration liabilities associated with business combinations; and (2) restructuring charges. A reconciliation of the GAAP and non-GAAP adjusted results is provided in the financial table included in this release. See also “Use of Non-GAAP Financial Measures” section.
Third Quarter 2019 Summary
The net loss for the quarter was
Revenues were
TFE gross margin was 28.2% compared to 40.2% in the third quarter of 2018 and 38.9% in the second quarter of 2019. The decline from the third quarter of 2018 and the second quarter of 2019 reflected unfavorable product mix.
Photonics gross margin was 43.1% compared to 35.5% in the third quarter of 2018 and 35.4% in the second quarter of 2019. The improvement from the second quarter of 2019 was primarily due to improved margins on both product sales and research and development contracts. The improvement from the third quarter of 2018 was primarily due to improved margins on research and development contracts. Consolidated gross margin was 33.4%, compared to 38.5% in the third quarter of 2018 and 37.5% in the second quarter of 2019.
R&D and SG&A expenses were
Order backlog totaled
The Company ended the quarter with
First Nine Months 2019 Summary
The net loss was
Revenues were
TFE gross margin was 32.4%, a decline compared to 39.6% in the first nine months of 2018, as a result of less favorable product mix. Photonics gross margin was 34.9% compared to 22.5% in the first nine months of 2018. The improvement from the first nine months of 2018 was primarily due to higher revenue levels and improved margins on both product sales and research and development contracts. Consolidated gross margin was 33.2%, compared to 34.8%, in the first nine months of 2018.
R&D and SG&A expenses were
Use of Non-GAAP Financial Measures
Management uses non-GAAP results to evaluate the Company’s operating and financial performance in light of business objectives and for planning purposes. These measures are not in accordance with GAAP and may differ from non-GAAP methods of accounting and reporting used by other companies.
Conference Call Information
The Company will discuss its financial results and outlook in a conference call today at
About
In our Thin-film Equipment business, we are a leader in the design and development of high-productivity, thin-film processing systems. Our production-proven platforms are designed for high-volume manufacturing of substrates with precise thin film properties, such as the hard drive media, display cover panel, and solar photovoltaic markets we serve currently.
In our Photonics business, we are a recognized leading developer of advanced high-sensitivity digital sensors, cameras and systems that primarily serve the defense industry. We are the provider of integrated digital imaging systems for most
For more information call 408-986-9888, or visit the Company's website at www.intevac.com.
200 Lean®, INTEVAC MATRIX®, INTEVAC VERTEX®, oDLC® and ENERGi® are registered trademarks and VERTEX Spectra™ is a trademark of
Safe Harbor Statement
This press release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”).
|
||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS |
||||||||||||
(Unaudited, in thousands, except per share amounts) |
||||||||||||
|
Three months ended |
|
Nine months ended |
|||||||||
|
|
|
|
|
|
|||||||
2019 |
2018 |
2019 |
2018 |
|||||||||
Net revenues |
|
|
|
|
|
|||||||
TFE |
$ |
17,116 |
$ |
12,108 |
|
$ |
49,325 |
$ |
45,745 |
|||
Photonics |
|
9,183 |
|
7,358 |
|
|
24,116 |
|
17,793 |
|||
Total net revenues |
|
26,299 |
|
19,466 |
|
|
73,441 |
|
63,538 |
|||
|
|
|
|
|
|
|||||||
Gross profit |
|
8,778 |
|
7,486 |
|
|
24,375 |
|
22,122 |
|||
Gross margin |
|
|
|
|
|
|||||||
TFE |
|
28.2% |
|
40.2% |
|
|
32.4% |
|
39.6% |
|||
Photonics |
|
43.1% |
|
35.5% |
|
|
34.9% |
|
22.5% |
|||
Consolidated |
|
33.4% |
|
38.5% |
|
|
33.2% |
|
34.8% |
|||
|
|
|
|
|
|
|||||||
Operating expenses |
|
|
|
|
|
|||||||
Research and development |
|
3,596 |
|
3,737 |
|
|
11,013 |
|
12,889 |
|||
Selling, general and administrative |
|
5,615 |
|
4,842 |
|
|
16,720 |
|
15,382 |
|||
Total operating expenses |
|
9,211 |
|
8,579 |
|
|
27,733 |
|
28,271 |
|||
Total operating loss |
|
(433) |
|
(1,093) |
|
|
(3,358) |
|
(6,149) |
|||
|
|
|
|
|
|
|||||||
Operating income (loss) |
|
|
|
|
|
|||||||
TFE |
|
(1,542) |
|
(907) |
|
|
(3,434) |
|
(2,197) |
|||
Photonics |
|
2,268 |
|
688 |
|
|
3,114 |
|
(966) |
|||
Corporate |
|
(1,159) |
|
(874) |
|
|
(3,038) |
|
(2,986) |
|||
Total operating loss |
|
(433) |
|
(1,093) |
|
|
(3,358) |
|
(6,149) |
|||
|
|
|
|
|
|
|||||||
Interest income and other income (expense), net |
|
126 |
|
186 |
|
|
448 |
|
464 |
|||
Net loss before income taxes |
|
(307) |
|
(907) |
|
|
(2,910) |
|
(5,685) |
|||
Provision for income taxes |
|
173 |
|
192 |
|
|
1,144 |
|
717 |
|||
Net loss |
$ |
(480) |
$ |
(1,099) |
|
$ |
(4,054) |
$ |
(6,402) |
|||
|
|
|
|
|
|
|||||||
Net loss per share |
|
|
|
|
|
|||||||
Basic and Diluted |
$ |
(0.02) |
$ |
(0.05) |
|
$ |
(0.18) |
$ |
(0.29) |
|||
|
|
|
|
|
|
|||||||
Weighted average common shares outstanding |
|
|
|
|
|
|||||||
Basic and Diluted |
|
23,130 |
|
22,719 |
|
|
22,992 |
|
22,429 |
|
||||||
CONDENSED CONSOLIDATED BALANCE SHEETS |
||||||
(In thousands, except par value) |
||||||
|
|
|
|
|||
2019 |
|
2018 |
||||
|
(Unaudited) |
|
(see Note) |
|||
ASSETS |
|
|
||||
|
|
|
||||
Current assets |
|
|
||||
Cash, cash equivalents and short-term investments |
$ |
30,299 |
$ |
34,791 |
||
Accounts receivable, net |
|
24,884 |
|
27,717 |
||
Inventories |
|
29,851 |
|
30,597 |
||
Prepaid expenses and other current assets |
|
1,872 |
|
2,528 |
||
Total current assets |
|
86,906 |
|
95,633 |
||
|
|
|
||||
Long-term investments |
|
5,447 |
|
4,372 |
||
Restricted cash |
|
1,355 |
|
1,169 |
||
Property, plant and equipment, net |
|
11,980 |
|
11,198 |
||
Operating lease right-of-use assets |
|
9,920 |
— |
|||
Intangible assets, net |
|
428 |
|
889 |
||
Other long-term assets |
|
8,248 |
|
8,809 |
||
Total assets |
$ |
124,284 |
$ |
122,070 |
||
|
|
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
||||
|
|
|
||||
Current liabilities |
|
|
||||
Current operating lease liabilities |
$ |
2,394 |
$ |
— |
||
Accounts payable |
|
5,544 |
|
6,053 |
||
Accrued payroll and related liabilities |
|
5,258 |
|
4,689 |
||
Other accrued liabilities |
|
3,650 |
|
4,952 |
||
Customer advances |
|
8,740 |
|
14,314 |
||
Total current liabilities |
|
25,586 |
|
30,008 |
||
|
|
|
||||
Non-current liabilities |
|
|
||||
Non-current operating lease liabilities |
|
9,354 |
— |
|||
Other long-term liabilities |
|
158 |
|
2,438 |
||
Total non-current liabilities |
|
9,512 |
|
2,438 |
||
|
|
|
||||
Stockholders’ equity |
|
|
||||
Common stock ( |
|
23 |
|
23 |
||
Additional paid-in capital |
|
186,938 |
|
183,204 |
||
|
|
(29,158) |
|
(29,047) |
||
Accumulated other comprehensive income |
|
371 |
|
378 |
||
Accumulated deficit |
|
(68,988) |
|
(64,934) |
||
Total stockholders’ equity |
|
89,186 |
|
89,624 |
||
Total liabilities and stockholders’ equity |
$ |
124,284 |
$ |
122,070 |
Note: Amounts as of
|
||||||||||||
RECONCILIATION OF GAAP TO NON-GAAP RESULTS |
||||||||||||
(Unaudited, in thousands, except per share amounts) |
||||||||||||
|
||||||||||||
|
Three months ended |
|
Nine months ended |
|||||||||
|
|
|
|
|
|
|
|
|||||
2019 |
|
2018 |
|
2019 |
|
2018 |
||||||
Non-GAAP Loss from Operations |
|
|
|
|
|
|||||||
Reported operating loss (GAAP basis) |
$ |
(433) |
$ |
(1,093) |
|
$ |
(3,358) |
$ |
(6,149) |
|||
Change in fair value of contingent consideration obligations1 |
— |
— |
|
|
7 |
|
8 |
|||||
Restructuring charges2 |
— |
— |
|
— |
|
95 |
||||||
Non-GAAP Operating Loss |
$ |
(433) |
$ |
(1,093) |
|
$ |
(3,351) |
$ |
(6,046) |
|||
|
|
|
|
|
|
|||||||
Non-GAAP Net Loss |
|
|
|
|
|
|||||||
Reported net loss (GAAP basis) |
$ |
(480) |
$ |
(1,099) |
|
$ |
(4,054) |
$ |
(6,402) |
|||
Change in fair value of contingent consideration obligations1 |
— |
— |
|
|
7 |
|
8 |
|||||
Restructuring charges2 |
— |
— |
|
— |
|
95 |
||||||
Non-GAAP Net Loss |
$ |
(480) |
$ |
(1,099) |
|
$ |
(4,047) |
$ |
(6,299) |
|||
|
|
|
|
|
|
|||||||
Non-GAAP Net Loss Per Diluted Share |
|
|
|
|
|
|||||||
Reported net loss per diluted share (GAAP basis) |
$ |
(0.02) |
$ |
(0.05) |
|
$ |
(0.18) |
$ |
(0.29) |
|||
Change in fair value of contingent consideration obligations1 |
— |
— |
|
— |
— |
|||||||
Restructuring charges2 |
— |
— |
|
— |
— |
|||||||
Non-GAAP Net Loss Per Diluted Share |
$ |
(0.02) |
$ |
(0.05) |
|
$ |
(0.18) |
$ |
(0.28) |
|||
Weighted average number of diluted shares |
|
23,130 |
|
22,719 |
|
|
22,992 |
|
22,429 |
1Results for all periods presented include changes in fair value of contingent consideration obligations associated with the Solar Implant Technology (SIT) acquisition in 2010.
2Results for the nine months ended
View source version on businesswire.com: https://www.businesswire.com/news/home/20191028005167/en/
Chief Financial Officer
(408) 986-9888
Investor Relations
(530) 265-9899
Source: